AML Clinical Trial
Official title:
Safety and Tolerability Trial of Abatacept-based Immunosuppression for Prevention of Acute GvHD During Unrelated Donor Hematopoietic Stem Cell Transplant
The primary objective of the study is to determine the safety and tolerability when adding abatacept to acute Graft versus Host Disease in transplants for malignant diseases using unrelated donor bone marrow or peripheral blood stem cell grafts.
Acute Graft versus Host Disease (aGvHD) is the most deadly complication facing children who
have allogeneic hematopoietic stem cell transplant (HSCT). aGvHD occurs, in large part,
because the T cells in the bone marrow graft do not "accept" the presence of the transplant
recipient's cells, and mount a severe, debilitating, and often deadly attack against the
recipient, striking the skin, the liver, and the gastrointestinal track, most prominently.
For patients receiving bone marrow from an unrelated donor, the rate of aGvHD can reach as
high as 80%, with up to half of patients dying from this complication. These serious outcomes
occur despite our best efforts at aGvHD prevention. Given the lack of success in preventing
aGvHD with current therapies, novel therapies to prevent this disease are desperately needed.
In this study, we plan to test a novel drug to prevent aGvHD. This drug, known as abatacept,
specifically blocks the activation pathway critical to T cell function known as "T cell
costimulation." In particular, it blocks the CD28-mediated costimulation pathway that is
critical for optimal T cell activation and proliferation. My research group has done
extensive pre-clinical work with this compound. Our work has demonstrated its efficacy in
inducing immune tolerance after transplantation in both mouse models and primate models. In
addition, patient trials have demonstrated that blocking CD28-directed T cell costimulation
can prevent T cell-mediated diseases, including rheumatoid arthritis and psoriasis, and can
improve solid organ transplant acceptance. Abatacept is currently FDA approved for use in
rheumatoid arthritis. Given this drug's safety and efficacy profile, we have been granted an
IND-exemption from the FDA for the inclusion of abatacept in a GvHD-prevention strategy.
This is a safety and tolerability study of the addition of abatacept to a GvHD-prophylaxis
regimen. Thus, the primary objective of the study is to determine the safety and tolerability
of the addition of abatacept to aGvHD prophylaxis in transplants for malignant hematologic
disease using unrelated donor bone marrow or peripheral blood stem cell grafts.
Three secondary objectives will also be addressed:
1. We will estimate the incidence and severity of aGvHD in patients receiving the
abatacept-based protocol.
2. We will determine the immune phenotype of donor cells in patients receiving abatacept.
3. We will determine the ability of donor T-cells in patients receiving abatacept to
respond to both polyclonal and recipient-specific immune stimulation.
These secondary objectives will allow us to determine the impact of abatacept-containing GvHD
prevention on both T cell alloreactivity and on T cell-mediated protective immunity.
This study is for patients older than 12 who have been diagnosed with high-risk leukemia and
for whom an unrelated bone marrow transplant is planned. We plan to enroll 10 patients on the
study, over a 1-year period from the opening of the trial. Of these ten patients, at least
five will be pediatric patients; the other five may be from adult patients taken care of by
Winship Cancer Center physicians. All clinical study coordination and biologic studies will
be performed by CHOA personnel.
Participants will receive one of two standard myeloablative conditioning regimens for their
stem cell transplant, and will receive an aGvHD prophylaxis regimen including cyclosporine,
methotrexate, and abatacept. They will have immunologic analysis for 1 year after transplant
and clinical analysis for 3 years after transplant.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03118466 -
Mitoxantrone, Etoposide, and Cytarabine (MEC) Plus Lenalidomide for Relapsed or Refractory Acute Myeloid Leukemia
|
Phase 2 | |
Not yet recruiting |
NCT06313437 -
Revumenib in Combination With 7+3 + Midostaurin in AML
|
Phase 1 | |
Withdrawn |
NCT03444649 -
Epacadostat, Idarubicin and Cytarabine (EIC) in AML
|
Phase 1 | |
Withdrawn |
NCT02905994 -
Volasertib Combined With Induction Chemotherapy in Acute Myeloid Leukemia
|
Phase 1 | |
Recruiting |
NCT02261779 -
Phase I/II Trial of ATRA and TCP in Patients With Relapsed or Refractory AML and no Intensive Treatment is Possible
|
Phase 1/Phase 2 | |
Completed |
NCT00246649 -
Stem Cell Transplant With Specially Treated Cells in Treating Patients With Acute Leukemia
|
N/A | |
Completed |
NCT00333190 -
CD8+ T Cell Depletion for GVHD Prophylaxis After Peripheral Blood Stem Cell Transplantation
|
N/A | |
Terminated |
NCT04079738 -
Study Augmenting TAK-659 Action in Relapsed/Refractory AML by Addition Ofthe Proteasome Inhibitor Ixazomib
|
Phase 1/Phase 2 | |
Completed |
NCT03466320 -
DEPLETHINK - LymphoDEPLEtion and THerapeutic Immunotherapy With NKR-2
|
Phase 1/Phase 2 | |
Withdrawn |
NCT03138395 -
iCare3: Monitoring Circulating Cancer DNA After Chemotherapy in MDS and AML
|
N/A | |
Terminated |
NCT01570465 -
Prospective Study on Severe Infections on Acute Myeloid Leukemia (AML) Patients
|
||
Completed |
NCT04443751 -
A Safety and Efficacy Study of SHR-1702 Monotherapy in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
|
Phase 1 | |
Terminated |
NCT03761069 -
Study of PTC299 (Emvododstat) in Relapsed/Refractory Acute Leukemias
|
Phase 1 | |
Completed |
NCT02631993 -
Photochemotherapy and Graft-versus-leukemia in Acute-leukemia
|
N/A | |
Completed |
NCT02575963 -
Lintuzumab-Ac225 in Older Acute Myeloid Leukemia (AML) Patients
|
Phase 1/Phase 2 | |
Completed |
NCT00863148 -
Allogeneic Stem Cell Transplant With Clofarabine, Busulfan and Antithymocyte Globulin (ATG) for Adult Patients With High-risk Acute Myeloid Leukemia/Myelodysplastic Syndromes (AML/MDS) or Acute Lymphoblastic Leukemia (ALL)
|
Phase 2 | |
Completed |
NCT00780598 -
Safety and Anti-Disease Activity of Oral Tosedostat (CHR-2797) in Elderly Subjects With Refractory or Relapsed AML
|
Phase 2 | |
Completed |
NCT00542971 -
Phase I-II Study of Idarubicin, Cytarabine, and Sorafenib (BAY43-9006)
|
Phase 1/Phase 2 | |
Completed |
NCT00761449 -
Lenalidomide in High-risk MDS and AML With Del(5q) or Monosomy 5
|
Phase 2 | |
Terminated |
NCT00176930 -
Stem Cell Transplant for Hematological Malignancy
|
N/A |